Malignant Peritoneal and Retroperitoneal Neoplasm

Observed

← altered in cohorts of

AVPR1A

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

BAZ2A

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CAND1

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

HSD17B6

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

NACA

70 / 92 cases (76 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

AGAP2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ATP23

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

ATP5F1B

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

AVIL

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

BIN2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CDK4

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CTDSP2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

CYP27B1

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

← altered in cohorts of

DYRK2

69 / 92 cases (75 %) · ssm · TCGA-ACC

—

Observed

Malignant Peritoneal and Retroperitoneal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 130show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 78 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	78	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 71 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 54 trials (21 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 33 trials (17 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 29 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 28 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 26 trials (7 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 24 trials (10 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 24 trials (3 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 21 trials (14 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 15 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 13 trials (5 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Malignant Peritoneal and Retroperitoneal Neoplasm	8	Observed	clinicaltrials	graph →

Malignant Peritoneal and Retroperitoneal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 130show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

78 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

71 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

54 trials (21 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

33 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall molecule

29 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

28 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

26 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

24 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

24 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Olaparibsmall molecule

21 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

15 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

13 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pemetrexedsmall molecule

10 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cabozantinibsmall molecule

8 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

Primary Peritoneal Carcinoma

Malignant Peritoneal and Retroperitoneal Neoplasm studied in …STUDIED_INderived10 of 631show all (up to 200)
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)	—	—	Primary Peritoneal Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06487481Phase 1 · recruiting Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Adrenal Cortical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 631 trials mapped (189 active)	—	—	Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07715903Phase 1 · not yet recruiting Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Adrenal Cortical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06057935Phase 2 · recruiting A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Peritoneal Malignant Mesothelioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07776691Phase 3 · recruiting A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Malignant Peritoneal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07708753Phase 3 · recruiting A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 631 trials mapped (189 active)	—	—	Platinum-Resistant Primary Peritoneal Carcinoma	1	Observed	clinicaltrials	graph →

Malignant Peritoneal and Retroperitoneal Neoplasm studied in …STUDIED_INderived10 of 631show all (up to 200)

→ studied in

NCT02345265Phase 2 · active not recruiting

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Carcinoma

→ studied in

NCT02446600Phase 3 · active not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Serous Adenocarcinoma

→ studied in

NCT02502266Phase 2/Phase 3 · active not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 631 trials mapped (189 active)

—

Observed

Primary Peritoneal Carcinoma

→ studied in

NCT05564377Phase 2 · recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

→ studied in

NCT06487481Phase 1 · recruiting

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma

→ studied in

NCT07504588Phase 2 · recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 631 trials mapped (189 active)

—

Observed

→ studied in

NCT07715903Phase 1 · not yet recruiting

Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Peritoneal Malignant Mesothelioma

→ studied in

NCT06057935Phase 2 · recruiting

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Malignant Peritoneal Neoplasm

→ studied in

NCT07776691Phase 3 · recruiting

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed

Platinum-Resistant Primary Peritoneal Carcinoma

→ studied in

NCT07708753Phase 3 · recruiting

A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers · condition mapped ALIAS · 631 trials mapped (189 active)

—

Observed